Premium
Treadmill exercise alleviates apoptotic nigrostriatal dopaminergic neuronal cell death and enhances cell proliferation in 6‐hydroxydopamine‐induced Parkinson’s rats
Author(s) -
Cho HanSam,
Song Wook,
Kim BoKyun,
Kim TaeSoo,
Kim ChangJu
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a930-a
Subject(s) - dopaminergic , substantia nigra , nigrostriatal pathway , dentate gyrus , parkinson's disease , medicine , endocrinology , hydroxydopamine , hippocampal formation , neuroscience , striatum , dopamine , psychology , disease
In Parkinson’s disease, progressive loss of dopaminergic neurons in substantia nigra leads to motor dysfunction and cognitive disturbances. Endogenous 6‐hydroxydopamine (6‐OHDA) is a neurotoxin which selectively injures catecholaminergic neurons and it causes progressive loss of nigral dopaminergic neurons. In the present study, we investigated the effects of treadmill exercise on short‐term memory, on apoptotic dopaminergic neuronal cell death and fiber loss, and on cell proliferation in the hippocampal dentate gyrus following 4 weeks after 6‐hydroxydopamine (6‐OHDA) injection into the striatum in rats. Four weeks after 6‐OHDA injection, the rats in the 6‐OHDA‐injection‐group exhibited significant rotational asymmetry following apomorphine challenge compared with the sham‐operated group. The rats in the exercise groups were put on the treadmill to run for 30 minutes once a day for 14 consecutive days starting 4 weeks after 6‐OHDA injection. In the 6‐OHDA‐injection group, treadmill exercise alleviated nigrostriatal dopaminergic cell loss and suppressed caspase‐3 expression in the substantia nigra. In addition, treadmill exercise enhanced short‐term memory and increased cell proliferation in the hippocampal dentate gyrus in the 6‐OHDA‐injection rats. As shown in the present study, treadmill exercise may provide therapeutic value for the treatment of Parkinson’s disease patients. This study was supported by the Brain Korea 21 Project in 2006.